Effects of Trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease

American Journal of Cardiology

Volumn 82, Issue 7, 1998, Pages 898-901

  Lu, Chunzeng ^a   Dabrowski, Pawel ^a   Fragasso, Gabriele ^a   Chierchia, Sergio L ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; TRIMETAZIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; ELECTROCARDIOGRAPHY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADMINISTRATION, ORAL; CORONARY DISEASE; CROSS-OVER STUDIES; DOBUTAMINE; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032189888     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00500-1     Document Type: Article

References (12)

1. 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987;286:97-110.
2. Kay L, Finelli C, Aussedat J, Guarnieri C, Rossi A. Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: effects on the energy state and mitochondrial function. Am J Cardiol 1995;76:45B-49B.
3. Maridonneau-Parini I, Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985;20:148-151.
4. Passeron J. Efficacy of trimetazidine in stable effort angina. Double-blind study against placebo. Presse Med 1986;15:1775-1778.
5. Michaelides AP, Vyssoulis GP, Bonoris PE, Psaros TK, Papadopoulos PD, Toutouzas PK. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment. Curr Ther Res 1989;46:565-576.
6. Levy S, and the Group of South of France Investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am J Cardiol 1995;76:12B-16B.
7. Dalla-Volta S, Maraglino G, Delia-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double blind, crossover study. Cardiovasc Drug Ther 1990;4:853-860.
8. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994;37:279-388.
9. Mody FV, Schelbert H, Coyle K Buxton D, Hansen H, Mohiuddin I, Sumida R, Singh B. Mechanism of action of a novel metabolically active antianginal agent (trimetazidine) delineated by PET. J Am Coll Cardiol 1996;27(suppl A9):132A.
10. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994;26:949-958.
11. Allibardi S, Chierchia SL, Cerioli V, Margonato V, Merati G, Neri G, Dell'Antonio G, Samaja M. Trimetazidine reduces post-ischemic dysfunction in rat hearts by decreasing energy requirements during underperfusion. J Cardiovas Pharmacol 1998; in press.
12. Goupit P. Pharmacocinétique de la trimetazidine. Concours Med 1987: 36(suppl):3447-3451.